Novo Nordisk Ownership

NOVA Stock  EUR 80.80  1.20  1.46%   
Novo Nordisk AS maintains a total of 2.25 Billion outstanding shares. Roughly 91.65 % of Novo Nordisk outstanding shares are held by general public with 0.007 pct. owned by insiders and only 8.34 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.

Novo Stock Ownership Analysis

The company has Price/Earnings To Growth (PEG) ratio of 2.0. Novo Nordisk AS last dividend was issued on the 24th of March 2023. The entity had 1:2 split on the 18th of September 2023. Novo Nordisk AS, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. NOVO NORDISK is traded on Frankfurt Stock Exchange in Germany. To find out more about Novo Nordisk AS contact Lars Jorgensen at 45 44 44 88 88 or learn more at https://www.novonordisk.com.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Novo Stock

When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.